SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT


Werte in diesem Artikel
Aktien

16.82 EUR -0.02 EUR -0.12 %

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws.

DJS Law Group

Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.

CASE DETAILS:  The complaint alleges that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having strong growth potential due to a lack of hindrances to broader use.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit---contact-the-djs-law-group-before-the-final-deadline---srpt-302496453.html

SOURCE DJS Law Group LLP

Aktuelle Sarepta Therapeutics Aktie News

Werbung

Sarepta Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sarepta Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
21.08.19 Sarepta Therapeutics Buy Needham & Company, LLC
01.10.18 Sarepta Therapeutics Overweight Cantor Fitzgerald
21.06.18 Sarepta Therapeutics Outperform Robert W. Baird & Co. Incorporated
20.06.18 Sarepta Therapeutics Buy Needham & Company, LLC
19.06.18 Sarepta Therapeutics Buy H.C. Wainwright & Co.